Login to Your Account

Atrix Gains FDA Approval Of Prostate Cancer Drug Eligard

By Karen Young

Friday, January 25, 2002
In what its chairman and CEO called a “transforming event” for the company, Atrix Laboratories Inc. received FDA approval for Eligard 7.5 mg, its one-month treatment for advanced prostate cancer.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription